Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaImmune tolerance induction for treating inhibitors in people with congenital haemophilia A or BImmune tolerance induction for treating inhibitors in people with congenital haemophilia A or BTAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in miceAnimal models of hemophiliaA review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Novel therapies for immune tolerance in haemophilia A.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Haemophilia therapies.International workshop on immune tolerance induction: consensus recommendations.Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceImmunomodulation for inhibitors in hemophilia A: the important role of Treg cellsThe use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.The reversal of inhibitors in congenital hemophilia.Inhibitor eradication with rituximab in haemophilia: where do we stand?Inhibitors - genetic and environmental factors.Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.Rituximab for treating inhibitors in people with inherited severe hemophilia.Factor VIII inhibitors: Advances in basic and translational science.Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Rituximab for adolescents with haemophilia and high titre inhibitors.Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab.Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.Dexamethasone promotes durable factor VIII -specific tolerance in hemophilia A mice via thymic mechanisms.
P2860
Q24186623-D13CD7F0-3848-4AAF-AC05-148C7A65FE44Q24195006-8766B9BC-CDB3-4506-80D5-8A521583EB58Q24202592-C7549E14-C887-46F4-ABEF-329DC3CA2C2DQ24302335-1608087C-4F78-4A3A-A85E-94BF1BA98482Q27012571-7656BEEA-29D0-49B6-ADC0-EE1863370BD0Q30442996-5986D254-4FF2-4CC6-8D8E-C429AB2864DEQ33469732-3284A94D-7714-4637-B6AE-D0294648966DQ34707338-57946C8B-0A87-4CD7-A8A9-C86087F10BBAQ36480548-E72930CB-4D2A-46F7-B23A-4FD3EE4A4B6AQ36661858-A74299ED-3386-4FC0-9E21-D41E2719E6BFQ36707550-3595F299-CFDE-484A-A7E6-82D4F81A17E4Q36810282-87FCBA58-1D6F-4EF3-BD9C-7E2BE01A4A60Q36861097-253B0104-7A63-4EA7-ABE8-7ACEB272B43DQ37012107-E68AF425-654E-46B0-813E-F2359FC7FDA7Q37176534-76A55AAB-7C8C-4C16-825B-E93408A1370FQ37244126-6F6A88B1-4161-47A9-BD71-C1623D741AB9Q37434315-A0EA1D76-21A6-4876-BBD0-58BD00A0D147Q37803130-8769DF2E-BF25-4621-9396-971CCC441CD0Q37924970-20958F4A-8EB6-4F9E-A591-C9E077A280C7Q37977140-987D93F6-C362-407E-A591-C1A4A0D1CB70Q38077139-E61A50C9-DCCC-496D-A23B-19F96793A082Q38195908-A6EBAAEF-5D5A-443C-B336-3B5BC35E63D9Q38206856-0942B8EA-37E6-44C1-AF83-7AC45E2F6FC5Q38222574-6543F004-054A-45FC-9F07-21A8F01D43B7Q38241445-44C80C23-C231-4AEC-83BE-17A7D5E4C01BQ38661525-57EE4C0F-97A2-4B0B-A7BC-ACFC9BE88915Q39266287-1D2DCF1B-4714-4FCE-9807-BFC596F5DAD0Q41924275-DA4281CE-A69B-4A92-90B3-FCB74F4A8AC0Q43007265-3514696F-9C36-4DF2-B68B-B084CD985099Q45838031-1E4E572A-B593-4A70-AC1E-962942241CE9Q45857818-139BED63-D647-4840-8289-84A712C9BF34Q45859168-F36020E6-C9DB-4D38-AC7E-F8E390FD70E6Q45863589-0A2D621C-014A-4DA7-B4B9-FE7DC2463093Q45863855-03407736-4FDD-47CA-B6BD-5220E71F823DQ45871306-A04B6E0F-E82D-4B48-A46F-15431D346350Q45875675-921BDDAD-9EBA-481E-A366-1FCC49628EFCQ45879318-ADCE6333-C0AA-44E4-ADD1-8A90559F74BDQ49866575-A731A9DD-8A50-48A1-AF7D-8EBEA789DBE0Q50622853-AFB7C559-F971-4182-B6B0-478213813304Q52315048-D233BCC1-A0C5-4A91-8910-AE43FFDD27FD
P2860
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@en
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@nl
type
label
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@en
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@nl
prefLabel
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@en
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@nl
P2093
P2860
P1433
P1476
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
@en
P2093
E Grunebaum
G E Rivard
Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada
J St Louis
V S Blanchette
P2860
P356
10.1111/J.1365-2516.2005.01170.X
P577
2006-01-01T00:00:00Z